Stop glamourising tanning
Read how you can help us STOP THE GLAMOURISATION OF TANNING.
Thank you, Community Fundraisers!
A shout out to all our wonderful community fundraisers, who have supported MIA in the last two months.
Personalised Immunotherapy Platform (PIP)
PIP is a tool developed by MIA to ensure advanced melanoma patients receive effective treatment the first time, based on their own genetics and tumour biology.
Join in Melanoma March 2023 and support Aussies impacted by melanoma
Melanoma March events across the country to fund ground-breaking clinical trial into psychological stresses experienced by advanced melanoma patients.
ABC-X Clinical Trial
The ABC-X clinical trial seeks to determine if the addition of radiotherapy, to combination immunotherapy, results in improved outcomes for patients with melanoma brain metastases.
A second penicillin moment for cancer treatment
In a world-first, an early phase trial of an mRNA personalised cancer vaccine has shown promising results for preventing melanoma recurrence in patients with resected high-risk melanoma (stage III and IV).
Community Fundraising Wrap Up October 2022
It was another big month of inspiring community fundraisers! From car shows, marathons and headshaves, to the selling of marmalade, monitors and swimming pools, we thank you all those who supported us over the past month.
MIA team receives 2022 Wildfire Highly Cited Publication Award
Read more about the Cancer Institute NSW Awards and the highly cited immunotherapy publication.
Melanoma Community Forum Hobart
Watch videos of presentations from the Melanoma Community Forum held in Hobart on 3rd November 2022.
MIA shares latest research breakthroughs at world’s largest melanoma conference
Tailoring skin checks based on personal risk, the impact of adjuvant and neo-adjuvant therapies, and the latest in personalised immunotherapy for advanced patients are amongst a plethora of research advances.